Skip to content
The Kids Research Institute Australia logo
Donate

Infectious Diseases Epidemiology

Our team’s vision is to reduce the burden of infectious diseases in children and their families through comprehensive approaches to understanding the burden of disease, developing and optimising diagnosis and treatment strategies and evaluating and informing current and future prevention programs.

Our group has a particular interest in acute lower respiratory infections, commonly known as chest infections.

These conditions include bronchiolitis and pneumonia and occurs secondary to viral and bacterial infections including viral pathogens respiratory syncytial virus (RSV), influenza, human metapneumovirus and parainfluenza virus and bacterial pathogens including Streptococcus pneumoniae and Bordetella pertussis. Chest infections are a major cause of childhood morbidity with some population subgroups experiencing higher rates of severe disease including Aboriginal and/or Torres Strait Islander children, those with co-morbidities and those from a lower socio-economic background.

The work of the Infectious Disease Epidemiology team centres around three key themes:

  • Burden of Disease – understanding pathogen-specific burden of disease, temporal and seasonal trends in disease and perinatal risk factors to disease in population groups using a range of data sources.
  • Prevention and Policy – evaluating current prevention policy, such as vaccination policy at local and population levels, incorporating assessment of vaccine coverage, cost effectiveness and overall program performance in reducing the incidence of disease. We also use data to advocate for new immunisation programs, including RSV.
  • Diagnosis and Treatment - developing ways to improve surveillance of and the diagnosis and treatment of severe respiratory infections in children through prospective cohort studies, clinical trials and use of administrative health data.

Our team employs an array of methodologies including epidemiological analyses of large-scale population-based linked administrative health data; statistical and mathematical modelling; undertaking prospective cohort studies and clinical trials; and conducting social research.

Team leader

Professor Hannah Moore
Professor Hannah Moore

OAM BSc (Hons) GradDipClinEpi PhD

Head, Infectious Diseases Research

Professor  Christopher Blyth
Professor Christopher Blyth

MBBS (Hons) DCH FRACP FRCPA PhD

Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and Infectious Diseases, Honorary and NHMRC Emerging Leadership Fellow

Team members (19)

Anita Williams
Anita Williams

MInfecDis MPhil(App Epi)

Research Officer, Infectious Diseases Epidemiology

Belaynew Taye
Belaynew Taye

MD, MPH, PhD

Research Officer, Infectious Disease Epidemiology

Carla Puca
Carla Puca

BSc, MPH, MIDI

Dr Minda Sarna
Dr Minda Sarna

M.App.Epid., PhD

Senior Research Officer

Huong Le
Huong Le

MA (Dev. Econ), MA (App. Stats), PhD (Econ)

Biostatistician & Data Analyst

Honorary Team Member

Carolyn Finucane

Carolyn Finucane

Research Nurse

Cathy Pienaar

Cathy Pienaar

Honorary Team Member

Charlie Holland

Charlie Holland

PhD Student

Damien Foo

Damien Foo

Research Officer

Daniel Oakes

Daniel Oakes

PhD Student

Dhruv Shah

Dhruv Shah

Program Manager, Infectious Diseases Epidemiology Team

Fiona Giannini

Fiona Giannini

Mathematical Modeller

Joanne Harvey

Joanne Harvey

Clinical Trial Coordinator

Kate Britton

Kate Britton

PhD Student

Leslie-Ann Conway

Leslie-Ann Conway

Honorary Team Member

Muna Jibril

Muna Jibril

Student

Zoe Clarke

Zoe Clarke

Project Coordinator

Evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children

High nasopharyngeal pneumococcal carriage density is associated with severe pneumonia; however, little is known about factors that affect pneumococcal carriage density including pneumococcal vaccination. We describe pneumococcal density by clinical and demographic factors, and effect of 13-valent pneumococcal conjugate vaccine (PCV13) on density in Papua New Guinea (PNG), Lao People’s Democratic Republic (Lao PDR) and Mongolia, 3–6 years following national PCV13 introduction.

The Hospitalization Cost of Pediatric Staphylococcus aureus Bacteremia

Staphylococcus aureus bacteremia (SAB) is the most common cause of childhood sepsis contributing to pediatric intensive care unit admission. The cost of adult SAB hospitalization is well described globally, but limited costing information is available for children. To bridge this knowledge gap, we investigated the cost of hospitalization in children with SAB in Australia.

Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024

In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.

Invasive mould infection in children – advances made or obstacles remaining?

Invasive mould infection (IMI) is a major cause of morbidity and mortality in immunocompromised children. Outcomes for paediatric patients with IMI remain poor, due in part to the limitations of available diagnostic tools and therapeutic agents.

Show all
Infectious Diseases Epidemiology

Videos